Showing results (241-250 of 324) with videos related to
Sort By:
Pageof 33
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 26, 2023
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR MutationsLecia V Sequist, James Chih-Hsin Yang, Nobuyuki Yamamoto, et al.The New England Journal of Medicine|June 1, 2026
Selpercatinib in Early-Stage RET Fusion-Positive Non-Small-Cell Lung CancerYi-Long Wu, Maximilian Hochmair, Yi Yang, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 25, 2015
Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global StudySai-Hong Ignatius Ou, Jin Seok Ahn, Luigi De Petris, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 18, 2020
Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLCMark M Awad, Shirish M Gadgeel, Hossein Borghaei, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 30, 2023
Pembrolizumab With or Without Lenvatinib for First-Line Metastatic NSCLC With Programmed Cell Death-Ligand 1 Tumor Proportion Score of at least 1% (LEAP-007): A Randomized, Double-Blind, Phase 3 TrialJames Chih-Hsin Yang, Baohui Han, Emmanuel De La Mora Jiménez, et al.JAMA Oncology|October 14, 2021
Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical TrialCaicun Zhou, Suresh S Ramalingam, Tae Min Kim, et al.The Lancet. Oncology|March 29, 2012
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trialVincent A Miller, Vera Hirsh, Jacques Cadranel, et al.JCO Global Oncology|September 30, 2024
Registry of Genetic Alterations of Taiwan Non-Small Cell Lung Cancer by Comprehensive Next-Generation Sequencing: A Real-World Cohort Study-Taiwan Cooperative Oncology Group T1521Bin-Chi Liao, Nai-Jung Chiang, Gee-Chen Chang, et al.Plos One|April 25, 2015
High Prevalence of the BIM Deletion Polymorphism in Young Female Breast Cancer in an East Asian CountryChing-Hung Lin, Chen-Yang Shen, Jih-Hsiang Lee, et al.The New England Journal of Medicine|April 30, 2015
AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancerPasi A Jänne, James Chih-Hsin Yang, Dong-Wan Kim, et al.Pageof 33